Data is temporarily not available
Acetazolamide - administration may increase serum concentration of phenmetrazine.
Alcohol - may increase serum concentration of phenmetrazine.
Ascorbic acid -lowering urinary pH, may enhance phenmetrazine excretion.
Furazolidone - phenmetrazine may induce a hypertensive response in patients taking furazolidone.
Guanethidine - phenmetrazine inhibits the antihypertensive response to guanethidine.
Haloperidol - limited evidence indicates that haloperidol may inhibit the effects of phenmetrazine but the clinical importance of this interaction is not established.
Lithium carbonate - isolated case reports indicate that lithium may inhibit the effects of phenmetrazine.
Monoamine oxidase inhibitor - severe hypertensive reactions have followed the administration of phenmetrazine to patients taking monoamine oxidase inhibitors.
Noradrenaline - phenmetrazine abuse may enhance the pressor response to noradrenaline.
Phenothiazines - phenmetrazine may inhibit the antipsychotic effect of phenothiazines, and phenothiazines may inhibit the anorectic effect of phenmetrazine.
Sodium bicarbonate - large doses of sodium bicarbonate inhibit the elimination of phenmetrazine, thus increasing the phenmetrazine effect.
Tobacco smoking - phenmetrazine appears to induce dose-related increases in cigarette smoking.
Tricyclic antidepressants - theoretically increases the effect of phenmetrazine, but clinical evidence is lacking.
Anorexia, insomnia, psychopathic personality disorders, suicidal tendencies, Gilles de la Tourette syndrome and other disorders, hyperthyroidism, narrow angle glaucoma, diabetes mellitis and cardiovascular diseases such as angina, hypertension and arrythmias (Dollery, 1991; Reynolds, 1996).